April 2010
Volume 51, Issue 13
Free
ARVO Annual Meeting Abstract  |   April 2010
Pharmacokinetics of Intravitreal Bevacizumab (Avastin) in Rabbits
Author Affiliations & Notes
  • C. Sinapis
    Department of Ophthalmology,
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • J. Routsias
    Department of Pathophysiology,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • D. Sinapis
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • A. Sinapis
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • V. Sinapi
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • A. Pantopoulou
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • S. Baltatzis
    Department of Ophthalmology,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • E. Patsouris
    Department of Pathology,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • D. Perrea
    Laboratory of Experimental Surgery and Surgical Research,
    School of Medicine, National and Capodistrian University of Athens, Athens, Greece
  • Footnotes
    Commercial Relationships  C. Sinapis, None; J. Routsias, None; D. Sinapis, None; A. Sinapis, None; V. Sinapi, None; A. Pantopoulou, None; S. Baltatzis, None; E. Patsouris, None; D. Perrea, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science April 2010, Vol.51, 2440. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      C. Sinapis, J. Routsias, D. Sinapis, A. Sinapis, V. Sinapi, A. Pantopoulou, S. Baltatzis, E. Patsouris, D. Perrea; Pharmacokinetics of Intravitreal Bevacizumab (Avastin) in Rabbits. Invest. Ophthalmol. Vis. Sci. 2010;51(13):2440. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To describe the pharmacokinetics of 1.25 mg of intravitreal bevacizumab (Avastin) in rabbits.

Methods: : The right eye of each of 20 rabbits was injected with 1.25 mg of intravitreal bevacizumab. Both eyes of each of 4 rabbits were enucleated at days 1, 3, 8, 15 and 29. Bevacizumab concentrations were measured in aqueous humor, vitreous and serum using two enzyme-linked immunosorbent assays (ELISA), one of low sensitivity (5ng/ml - 0.1 µg/ml) and one of high sensitivity (10pg/ml - 5ng/ml).

Results: : Maximum vitreous (406.25 µg/ml) and aqueous humor (5.83 µg/ml) concentrations of bevacizumab in the right eye were measured 1 day after drug administration. Concentrations of >5 µg/ml bevacizumab were maintained in the vitreous 29 days after injection. A maximum serum concentration of 0.412 µg/ml was achieved 8 days after intravitreal injection and the concentration fell at 0.032 µg/ml 29 days after injection. Very low concentrations of bevacizumab were detected in the fellow uninjected eye. Concentrations of bevacizumab in the vitreous of the fellow eye reached their peak 8 days after injection, at 0.335 ng/ml, and declined to 0.2175 ng/ml at 4 weeks. Concentrations of bevacizumab in the aqueous humor of the fellow eye reached their peak 8 days after injection, at 1.6125 ng/ml, and declined to 0.105ng/ml at 4 weeks.

Conclusions: : The maximum concentrations of bevacizumab in both vitreous and aqueous humor of right eye were reached at 1 day after injection while in the serum at 8 days after injection. Very small amounts of bevacizumab were detected in the fellow uninjected eye with the maximum concentrations measured at 8 days after injection for both the aqueous humor and vitreous.

Keywords: growth factors/growth factor receptors • immunohistochemistry 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×